이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Fulgent Genetics 관리
관리 기준 확인 2/4
Fulgent Genetics' CEO는 Ming Hsieh, May2016 에 임명되었습니다 의 임기는 8.08 년입니다. 총 연간 보상은 $ 5.31M, 18.8% 로 구성됩니다. 18.8% 급여 및 81.2% 보너스(회사 주식 및 옵션 포함). 는 $ 172.52M 가치에 해당하는 회사 주식의 29.15% 직접 소유합니다. 172.52M. 경영진과 이사회의 평균 재임 기간은 각각 4.3 년과 3.3 년입니다.
주요 정보
Ming Hsieh
최고 경영자
US$5.3m
총 보상
| CEO 급여 비율 | 18.8% |
| CEO 임기 | 8.1yrs |
| CEO 소유권 | 29.1% |
| 경영진 평균 재임 기간 | 4.3yrs |
| 이사회 평균 재임 기간 | 3.3yrs |
최근 관리 업데이트
Recent updates
Fulgent Genetics: Growth Is Returning
Jun 06Shareholders May Be Wary Of Increasing Fulgent Genetics, Inc.'s (NASDAQ:FLGT) CEO Compensation Package
May 10
Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report
May 07Are Investors Undervaluing Fulgent Genetics, Inc. (NASDAQ:FLGT) By 32%?
Mar 01Fulgent Genetics: Buy Growth Ahead Below Liquidation Value
Feb 21Subdued Growth No Barrier To Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Price
Jan 17Is Fulgent Genetics (NASDAQ:FLGT) Using Debt Sensibly?
Dec 14Fulgent Genetics (NASDAQ:FLGT) Has Debt But No Earnings; Should You Worry?
Aug 09Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report
May 09Fulgent Genetics (NASDAQ:FLGT) Is Looking To Continue Growing Its Returns On Capital
Apr 19Why We Like The Returns At Fulgent Genetics (NASDAQ:FLGT)
Jan 15Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?
Dec 28What Does The Future Hold For Fulgent Genetics, Inc. (NASDAQ:FLGT)? These Analysts Have Been Cutting Their Estimates
Nov 16Why Fulgent Genetics, Inc. (NASDAQ:FLGT) Could Be Worth Watching
Oct 27Wait For Fulgent Genetics To Grow Up
Oct 13We Like Fulgent Genetics' (NASDAQ:FLGT) Returns And Here's How They're Trending
Sep 19Fulgent Genetics (NASDAQ:FLGT) Seems To Use Debt Rather Sparingly
Sep 05Fulgent Genetics: Poised To Survive Its Post-Covid Hangover
Jul 26Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Low P/E No Reason For Excitement
Jul 21Fulgent Genetics (NASDAQ:FLGT) Is Investing Its Capital With Increasing Efficiency
Jun 04Fulgent Is Putting Its Cash Bonanza To Work
May 15These 4 Measures Indicate That Fulgent Genetics (NASDAQ:FLGT) Is Using Debt Safely
May 04Fulgent Genetics: Now The Going Could Get Much Tougher
Apr 10Fulgent Genetics: COVID Bolstered The Underlying Business
Mar 17Fulgent Genetics: Somewhat Disappoints With A Marked Slowdown In Its NGS Business
Feb 27Fulgent Genetics Stock: 35% Off Its Recent Highs - It Is Now A Buy
Feb 09Fulgent Genetics: Sell Volatility
Jan 26Fulgent Genetics (NASDAQ:FLGT) Has A Rock Solid Balance Sheet
Jan 25Fulgent Genetics: Improving Outlook, But Shares Aren't Quite A Buy
Jan 09Fulgent Genetics: Undervalued, High Growth, And A COVID Hedge To Boot
Dec 20CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$166m |
| Dec 31 2023 | US$5m | US$1m | -US$168m |
| Sep 30 2023 | n/a | n/a | -US$64m |
| Jun 30 2023 | n/a | n/a | -US$49m |
| Mar 31 2023 | n/a | n/a | -US$26m |
| Dec 31 2022 | US$5m | US$948k | US$143m |
| Sep 30 2022 | n/a | n/a | US$272m |
| Jun 30 2022 | n/a | n/a | US$392m |
| Mar 31 2022 | n/a | n/a | US$461m |
| Dec 31 2021 | US$6m | US$664k | US$507m |
| Sep 30 2021 | n/a | n/a | US$569m |
| Jun 30 2021 | n/a | n/a | US$493m |
| Mar 31 2021 | n/a | n/a | US$417m |
| Dec 31 2020 | US$248k | US$240k | US$214m |
| Sep 30 2020 | n/a | n/a | US$48m |
| Jun 30 2020 | n/a | n/a | US$3m |
| Mar 31 2020 | n/a | n/a | -US$459k |
| Dec 31 2019 | US$240k | US$240k | -US$411k |
| Sep 30 2019 | n/a | n/a | -US$2m |
| Jun 30 2019 | n/a | n/a | -US$4m |
| Mar 31 2019 | n/a | n/a | -US$6m |
| Dec 31 2018 | US$240k | US$240k | -US$6m |
| Sep 30 2018 | n/a | n/a | -US$5m |
| Jun 30 2018 | n/a | n/a | -US$6m |
| Mar 31 2018 | n/a | n/a | -US$5m |
| Dec 31 2017 | US$240k | US$240k | -US$3m |
보상 대 시장: Ming 의 총 보상 ($USD 5.31M )은 US 시장( $USD 2.46M ).
보상과 수익: 회사가 수익성이 없는 동안 Ming 의 보상이 증가했습니다.
CEO
Ming Hsieh (68 yo)
8.1yrs
테뉴어
US$5,309,167
보상
Mr. Ming Hsieh has been an Independent Director of Fortinet, Inc. since April 2013. He is the Founder of Fulgent Genetics, Inc. and had been its President until May 2022 & serves as its Chief Executive Off...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Chairman & CEO | 8.1yrs | US$5.31m | 29.15% $ 172.5m | |
| COO & President | 6.2yrs | US$1.79m | 1.38% $ 8.2m | |
| Chief Financial Officer | 8.4yrs | US$1.78m | 0.38% $ 2.2m | |
| Chief Scientific Officer & Laboratory Director | 7.8yrs | US$1.49m | 2.83% $ 16.7m | |
| General Counsel & Chief Privacy Officer | 2.1yrs | 데이터 없음 | 데이터 없음 | |
| VP of Operations & Compliance and GM of Houston Office | 3.7yrs | 데이터 없음 | 데이터 없음 | |
| Vice President of Business Development & Sales | 9.4yrs | 데이터 없음 | 데이터 없음 | |
| Vice President of Human Resources | 2.1yrs | 데이터 없음 | 데이터 없음 | |
| Chief Commercial Officer | 4.3yrs | 데이터 없음 | 데이터 없음 | |
| Chief Medical Officer | 3.1yrs | 데이터 없음 | 데이터 없음 | |
| President & Chief Scientific Officer of Fulgent Pharma | 1.6yrs | 데이터 없음 | 데이터 없음 |
4.3yrs
평균 재임 기간
58yo
평균 연령
경험이 풍부한 관리: FLGT 의 관리팀은 경험 ( 4.3 년 평균 재직 기간)으로 간주됩니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Chairman & CEO | 8.1yrs | US$5.31m | 29.15% $ 172.5m | |
| Independent Non-Employee Director | 1.4yrs | US$625.60k | 0.0040% $ 23.5k | |
| Independent Director | 4.8yrs | US$270.50k | 0.062% $ 369.1k | |
| Independent Non-Employee Director | 1.8yrs | US$268.50k | 0.0080% $ 47.1k |
3.3yrs
평균 재임 기간
67yo
평균 연령
경험이 풍부한 이사회: FLGT 의 이사회는 경험(평균 재직 기간 3.3 년)으로 간주됩니다.